Ultragenyx Pharmaceutical Inc. (RARE) company profile
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
About Ultragenyx Pharmaceutical
Pharmaceutical Preparations, SIC 2834
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company engaged in the identification, acquisition, development, and commercialization of therapeutic products. Its business centers on treatments for serious medical conditions, with commercial products and collaborations that include therapies such as Crysvita, Dojolvi, Mepsevii, and Evkeeza. The organization collaborates with biopharmaceutical partners and institutions to advance research, clinical development, licensing arrangements, and product distribution.
The company operates in North America and engages in commercial, licensing, and development activities across international regions, including Latin America, Europe, the Middle East, and the Asia-Pacific territory. It maintains facilities for research, development, and manufacturing. Ultragenyx Pharmaceutical Inc. is organized under the laws of Delaware and maintains its principal executive offices in Novato, California.
Summary of the business section of Ultragenyx Pharmaceutical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ultragenyx Pharmaceutical Inc.
- Founded
- 2010
- Headquarters
- Novato, CA
- Address
- 60 Leveroni Court 94949
- Phone
- (415) 483-8800
- Website
- www.ultragenyx.com
- Employees
- 1,371, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- RARE
- Exchange
- Nasdaq
- IPO date
- Jan 31, 2014
- Shares outstanding
- 99M, Jul 31, 2026
- Public float
- $3.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1515673
- CUSIP
- 90400D108
- ISIN
- US90400D1081
- FIGI
- BBG001RWPDW6
- Share class FIGI
- BBG001V2MJJ2
- LEI
- 529900EV44GVDN1DCX77
- EIN
- 27-2546083
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Emil D. Kakkis | President & CEO, Director | 2,694,724 |
| Howard Horn | Chief Financial Officer | 89,229 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | 67,863 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | 92,562 |
| Eric Crombez | EVP and Chief Medical Officer | 111,189 |
| John Richard Pinion | See Remarks | 133,142 |
| Dennis Karl Huang | See Remarks | 147,845 |
| Erik Harris | EVP & Chief Commercial Officer | 118,410 |
| Thomas Richard Kassberg | CBO & EVP | 265,238 |
| Corazon (Corsee) D. Sanders | Director | 21,095 |
| Daniel G. Welch | Director | 40,441 |
| Michael Narachi | Director | 40,441 |
| Deborah Dunsire | Director | 38,566 |
| Amrit Ray | Director | 31,116 |
| Shehnaaz Suliman | Director | 27,951 |
| Matthew K. Fust | Director | 33,696 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $11.41M | -$1.29M | $3.83M | $17 | $120 |
| FY2024 | $13.72M | $8.19M | $4.25M | $30 | $91 |
| FY2023 | $13.08M | $11.29M | $4.52M | $35 | $92 |
| FY2022 | $12.14M | $3.31M | $3.91M | $33 | $89 |
| FY2021 | $9.52M | -$2.15M | $3.31M | $61 | $99 |
| FY2020 | $5.14M | $22.73M | $2.71M | $324 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Emil D. Kakkis, M.D., Ph.D. President and Chief Executive Officer | $861.10K | $8.36M | $1.85M | $299.66K | $32.48K | $11.41M | -17% |
| Howard Horn Chief Financial Officer, Corporate Strategy and Executive Vice President | $604.39K | $2.24M | $663.13K | $227.63K | $14.00K | $3.75M | -13% |
| Erik Harris Chief Commercial Officer and Executive Vice President | $619.69K | $2.41M | $712.26K | $291.56K | $14.00K | $4.05M | -6% |
| Eric Crombez, M.D. Chief Medical Officer and Executive Vice President | $630.23K | $2.41M | $712.26K | $238.13K | $14.00K | $4.00M | -7% |
| Karah Parschauer Chief Legal Officer and Corporate Affairs, Executive Vice President | $585.34K | $2.08M | $614.01K | $220.53K | $14.00K | $3.51M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 31, 2014
- Offer price
- $21.00
- Securities offered
- 5,760,369
- Gross proceeds
- $120.97M
- Exchange
- Nasdaq
- First trading day
- Jan 31, 2014
- First-day close
- $42.25+101.2%
- Lock-up ends (est.)
- Jul 30, 2014
“The initial public offering price is $21.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,371 total employees, of which 916 are in research and development and 455 are in sales, general, and administrative.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 3, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 18, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 10, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 7, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 10, 2017 | Tender offer | Third-party tender offer for the company's shares |
| Jan 31, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 24, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?